Isabelle Ray-Coquard discusses abstracts presented at the ESMO Congress 2022:
- LBA29: Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
- 517O: Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
- 518O: Overall survival results from ARIEL4: a phase 3 study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation
This video was supported with an unrestricted grant from Bayer Healthcare.
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.